The National Cancer Institute of Bari (Istituto di Ricovero e Cura a Carattere Scientifico, IRCCS) has been involved since the conception of the project of the Italian Ministry for Health aimed to validate the applicability of the Organisation of European Cancer Institutes (OECI) accreditation and designation (A&D) model to the Network of Italian Cancer Centers, IRCCS, of Alleanza Contro il Cancro. The self-assessment phase of the Institute started in September 2013 and ended in June 2014. All documents and tools were transferred to the OECI A&D Board in June 2014 and a 2-day peer review visit was conducted in October 2014 by an international qualified audit team. The Institute received its final designation and certification in June 2015. The OECI A&D Board, in its final report, came to the conclusion that Istituto Tumori "Giovanni Paolo II" of Bari has a strong research component with some essential elements of comprehensive cancer care still under development; the lack of a system for using outcome data for the strategic management approach to decision-making and missing a regular internal audit system eventually helping further quality improvement were reported as examples of areas with opportunities for improvement. The OECI A&D process represented a great opportunity for the cancer center to benchmark the quality of its performance according to standard parameters in comparison with other international centers and to further develop a participatory group identity. The common goal of accreditation was real and participatory with long-lasting positive effects. We agree with the OECI comments about the next areas of work in which the Institute could produce future further efforts: the use of its powerful IT system as a means for outcome analysis and empowerment projects for its cancer patients.

Download full-text PDF

Source
http://dx.doi.org/10.5301/tj.5000467DOI Listing

Publication Analysis

Top Keywords

oeci a&d
12
istituto tumori
8
june 2014
8
a&d board
8
system outcome
8
cancer
6
oeci
5
european accreditation
4
accreditation istituto
4
tumori giovanni
4

Similar Publications

Background: European cancer programmes and policies lack a unified health-related quality of life (HRQoL) assessment tool. The European oncology quality of life toolkit (EUonQoL-Kit) is a novel set of HRQoL questionnaires, co-designed with cancer patients and survivors, translated and culturally adapted into 31 European languages, and with both static and dynamic electronic administration modes. The main aim of this study is the psychometric assessment of the static version.

View Article and Find Full Text PDF
Article Synopsis
  • The European Cancer Organisation's Essential Requirements for Quality Cancer Care (ERQCC) provide guidance on how to improve cancer treatment, focusing on ovarian cancer specifically.
  • Ovarian cancer patients experience low cure rates due to inconsistent treatment and a need for specialized care, which should be provided in dedicated centers by qualified professionals.
  • Centralized, patient-centered care throughout the entire treatment journey is essential for better outcomes but is not yet widely implemented across many European countries.
View Article and Find Full Text PDF

Standardization through education of molecular pathology: a spotlight on the European Masters in Molecular Pathology.

Virchows Arch

November 2024

Laboratory of Clinical and Experimental Pathology, Hospital-Related Biobank BB0033-00025, Nice University Hospital, University Côte d'Azur, FHU OncoAge, IHU RespirERA, 06000, Nice, France.

Despite advancements in precision medicine, many cancer patients globally, particularly those in resource-constrained environments, face significant challenges in accessing high-quality molecular testing and targeted therapies. The considerable heterogeneity in molecular testing highlights the urgent need to harmonize practices across Europe and beyond, establishing a more standardized and consistent approach in MP laboratories. Professionals, especially molecular pathologists, must move beyond traditional education to cope with this heterogeneity.

View Article and Find Full Text PDF

Merkel-cell carcinoma: ESMO-EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-up.

ESMO Open

May 2024

Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, Medical Oncology Unit, University of Brescia, ASST Spedali Civili, Brescia, Italy.

• This ESMO Clinical Practice Guideline provides key recommendations for managing Merkel-cell carcinoma (MCC). • Recommendations are based on available scientific data and the multidisciplinary group of experts’ collective opinion. • The guideline covers clinical and pathological diagnosis, staging and risk assessment, treatment and follow-up.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!